Anti-gp210 and anti-Sp100 antibodies in primary biliary cholangitis

Lamine, Zeineb Ben; Jazia, I. Ben; Ahmed, M.; Slama, A. Ben; Baccouche, A.; Slama, Foued; Jemaa, A.; Ghedira, Ibtissem; Mankaï, Amani

doi:10.1016/j.ajg.2021.05.006

Cited by 7 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could be inferred, as S‐PBC, 24 CTD‐PBC was prone to onset in middle‐aged female despite in young population with SLE. There were no significant differences between S‐PBC and CTD‐PBC groups for the other characteristics including gender distribution, ALP level and positive rate of antibodies (anti‐PDC‐E2, anti‐gp210 and anti‐sp100 antibody) specific for PBC 25 …”

Section: Discussionmentioning

confidence: 77%

“…There were no significant differences between S-PBC and CTD-PBC groups for the other characteristics including gender distribution, ALP level and positive rate of antibodies (anti-PDC-E2, anti-gp210 and anti-sp100 antibody) specific for PBC. 25 To address the possible role of 2OA in the pathogenesis of S-PBC and CTD-PBC, firstly, we investigated the prevalence of autoantibodies to LA, 2OA, LA-ILD and 2OA-ILD in the two groups. The result showed that there was no difference in the antibody reactivities to LA-ILD, 2OA-ILD and LA between the two groups; meanwhile, the positive percentages for these antibodies also presented…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Differential immune response to xenobiotic‐modified self‐molecule in simple and connective tissue disease‐associated primary biliary cholangitis

et al. 2022

Liver International

View full text Add to dashboard Cite

Background and Aims: Our previous studies demonstrated that 2-octynoic acid (2OA) might alter the conformational structure of the inner lipoic acid (LA) binding domain (ILD) in the E2 subunit of pyruvate dehydrogenase complex (PDC-E2), leading to the loss of immune tolerance in simple primary biliary cholangitis (S-PBC). Here, we further explore if this etiological mechanism also accounts for connective tissue diseaseassociated PBC (CTD-PBC).Methods: Intein-mediated protein ligation was used to prepare ILD, LA-ILD and 2OA-ILD, and their reactivity with serum samples from 124 S-PBC and 132 CTD-PBC patients was examined. The antibodies to LA, 2OA, LA-ILD and 2OA-ILD, the isotypes of antibodies to LA, 2OA and ILD, were comparatively detected between the two patient groups by enzyme-linked immunosorbent assay and immunoblotting.Results: Both the percentage and reactivity of antibody to 2OA in S-PBC were significantly higher than in CTD-PBC. Antibodies to 2OA and to LA between the two groups separately shared the same characteristics. Remarkably, coexistence of the antibodies to LA-ILD and to 2OA, and coexistence of the antibodies to LA and to 2OA in S-PBC were both significantly more frequent than in CTD-PBC, whereas the percentage of anti-LA antibody without anti-2OA antibody in S-PBC was markedly lower than in CTD-PBC. Moreover, the isotype of antibody to LA was predominantly IgG in CTD-PBC, whilst this isotype was mainly IgM in S-PBC. Conclusion:Xenobiotic 2OA might play less important pathogenic role in CTD-PBC than in S-PBC, suggesting that different underlying mechanisms are involved in their immune intolerance to PDC-E2.

show abstract

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Differential immune response to xenobiotic‐modified self‐molecule in simple and connective tissue disease‐associated primary biliary cholangitis

et al. 2022

Liver International

View full text Add to dashboard Cite

show abstract

“…The specificity of anti-sp100 and anti-gp210 antibodies are 100% and 96.5%, respectively, while they have a sensitivity of 28.3% and 29.2%, respectively. The positive and negative predictive values of the anti-sp100 antibodies were 100% and 43.3%, respectively [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: A Retrospective Diagnosis

Al-Handola¹,

Chinnappan²,

Hussain³

et al. 2023

Cureus

View full text Add to dashboard Cite

Primary biliary cholangitis (PBC) is an inflammatory cholestatic disease that tends to worsen, leading to hepatic cirrhosis and portal hypertension. We present a case of a middle-aged female who presented with progressively worsening generalized itch; the examination was significant only for urticarial rash and facial swelling. Investigation revealed direct hyperbilirubinemia, mildly elevated transaminase, and significant elevation of alkaline phosphatase. A differential was performed with labs including antimitochondrial antibodies (AMA) for PBC, hepatitis panel, anti-smooth muscle antibodies for autoimmune hepatitis, and tissue transglutaminase IgA for celiac disease, all of which were unremarkable. The patient was empirically treated with ursodeoxycholic acid (UDCA). Given the excellent clinical response at the three-week follow-up to treatment despite negative AMA, further testing with anti-sp100 and anti-gp210 was pursued, which returned positive for anti-sp100, confirming the diagnosis of PBC.

show abstract

Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis

Jaskowski¹,

Nandakumar²,

Novis³

et al. 2023

Clinica Chimica Acta

View full text Add to dashboard Cite

Anti-gp210 and anti-Sp100 antibodies in primary biliary cholangitis

Cited by 7 publications

References 35 publications

Differential immune response to xenobiotic‐modified self‐molecule in simple and connective tissue disease‐associated primary biliary cholangitis

Differential immune response to xenobiotic‐modified self‐molecule in simple and connective tissue disease‐associated primary biliary cholangitis

Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: A Retrospective Diagnosis

Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis

Contact Info

Product

Resources

About